Display options
Cite
Mizoshita T, Tanida S, Tsukamoto H, et al. Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus. ISRN Gastroenterol. 2013;2013:304894doi: 10.1155/2013/304894.
Mizoshita, T., Tanida, S., Tsukamoto, H., Ozeki, K., Katano, T., Ebi, M., Mori, Y., Kataoka, H., Kamiya, T., & Joh, T. (2013). Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus. ISRN gastroenterology, 2013304894. https://doi.org/10.1155/2013/304894
Mizoshita, Tsutomu, et al. "Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus." ISRN gastroenterology vol. 2013 (2013): 304894. doi: https://doi.org/10.1155/2013/304894
Mizoshita T, Tanida S, Tsukamoto H, Ozeki K, Katano T, Ebi M, Mori Y, Kataoka H, Kamiya T, Joh T. Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus. ISRN Gastroenterol. 2013 Apr 09;2013:304894. doi: 10.1155/2013/304894. Print 2013. PMID: 23691335; PMCID: PMC3649514.
Copy Download .nbib Format: NLM
Share it on

ISRN Gastroenterol. 2013 Apr 09;2013:304894. doi: 10.1155/2013/304894. Print 2013.

Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus.

ISRN gastroenterology

Tsutomu Mizoshita, Satoshi Tanida, Hironobu Tsukamoto, Keiji Ozeki, Takahito Katano, Masahide Ebi, Yoshinori Mori, Hiromi Kataoka, Takeshi Kamiya, Takashi Joh

Affiliations

  1. Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.

PMID: 23691335 PMCID: PMC3649514 DOI: 10.1155/2013/304894

Abstract

Background. Tacrolimus (FK506) is effective for patients with ulcerative colitis (UC). However, there are few reports on tacrolimus therapy (TT) with respect to the relationship with endoscopic and clinicopathologic findings. Methods. Thirty patients with moderate/severe active UC refractory to or dependent on corticosteroid were treated with oral tacrolimus. The expression of ectopic MUC5AC in the colon was pathologically analyzed before and at 12 weeks after TT, evaluating the Mayo score and steroid-sparing effects. Results. Both mean disease and endoscopic activity index scores were reduced at levels of statistical significance in 26 UC patients receiving more than one month of TT (P < 0.0001). The dose of prednisolone was reduced by a statistically significant amount (P = 0.00022), and 14 of the 26 patients (53.8%) had steroid-free status 12 weeks after TT. The decrease in ectopic MUC5AC expression in the mucous cells of the colon was significantly associated with endoscopic improvement of inflammation in the UC patients with TT (P = 0.043). Loss of ectopic MUC5AC expression was detected in all patients who had complete response. Conclusions. Tacrolimus appears to be effective for the treatment of moderate/severe UC patients. Loss of ectopic MUC5AC expression may be important for pathologic remission in the colon of UC patients.

References

  1. Ther Apher. 1998 May;2(2):134-41 - PubMed
  2. J Crohns Colitis. 2007 Sep;1(1):35-40 - PubMed
  3. Case Rep Gastroenterol. 2011 Apr 12;5(1):144-51 - PubMed
  4. Histol Histopathol. 2007 Mar;22(3):251-60 - PubMed
  5. Aliment Pharmacol Ther. 2003 Aug 15;18(4):415-23 - PubMed
  6. Gastroenterology. 2001 Aug;121(2):255-60 - PubMed
  7. Lancet. 2007 May 12;369(9573):1641-57 - PubMed
  8. Gastroenterology. 1987 Jun;92(6):1894-8 - PubMed
  9. Dig Dis Sci. 2004 Apr;49(4):565-71 - PubMed
  10. Am J Gastroenterol. 1998 Oct;93(10):1860-6 - PubMed
  11. Aliment Pharmacol Ther. 2008 Sep 1;28(5):589-97 - PubMed
  12. J Gastroenterol Hepatol. 2010 May;25(5):886-91 - PubMed
  13. Gut. 2006 Sep;55(9):1255-62 - PubMed
  14. Gut. 2001 Oct;49(4):544-51 - PubMed
  15. J Clin Gastroenterol. 2011 Jul;45(6):526-30 - PubMed
  16. Gut. 1997 Apr;40(4):443-8 - PubMed
  17. J Cancer Res Clin Oncol. 2003 Dec;129(12):727-34 - PubMed
  18. Inflamm Bowel Dis. 2011 Mar;17(3):802-8 - PubMed
  19. Inflamm Bowel Dis. 2008 Jan;14(1):7-12 - PubMed
  20. Am J Gastroenterol. 2006 May;101(5):1048-56 - PubMed
  21. Virchows Arch. 2006 Jun;448(6):756-62 - PubMed
  22. Intern Med. 2012;51(6):595-9 - PubMed
  23. Inflamm Bowel Dis. 2012 May;18(5):803-8 - PubMed
  24. Inflamm Bowel Dis. 2002 Sep;8(5):317-24 - PubMed
  25. Inflamm Bowel Dis. 2007 Feb;13(2):129-34 - PubMed
  26. J Crohns Colitis. 2012 Aug;6(7):750-5 - PubMed
  27. Jpn J Cancer Res. 2001 Jul;92(7):755-61 - PubMed
  28. Helicobacter. 2005 Apr;10(2):97-106 - PubMed
  29. Drugs. 1978 Sep;16(3):238-55 - PubMed
  30. Cochrane Database Syst Rev. 2008 Jul 16;(3):CD007216 - PubMed
  31. Hepatogastroenterology. 2009 Jan-Feb;56(89):252-3 - PubMed
  32. Aliment Pharmacol Ther. 2010 May;31(9):1036-41 - PubMed
  33. J Gastroenterol. 2000;35(8):635-40 - PubMed
  34. Ther Apher Dial. 2003 Feb;7(1):48-59 - PubMed
  35. J Gastroenterol. 2007 Jan;42(1):16-25 - PubMed
  36. Am J Gastroenterol. 2009 Dec;104(12):2990-5 - PubMed
  37. Clin J Gastroenterol. 2012 Aug;5(4):302-6 - PubMed
  38. J Pediatr Gastroenterol Nutr. 2007 Sep;45(3):306-11 - PubMed
  39. Int J Cancer. 2007 Oct 1;121(7):1543-9 - PubMed
  40. Scand J Gastroenterol. 2007 Feb;42(2):221-7 - PubMed
  41. N Engl J Med. 1987 Dec 24;317(26):1625-9 - PubMed
  42. J Gastroenterol. 2011 Feb;46(2):129-37 - PubMed
  43. J Pediatr Gastroenterol Nutr. 2004 May;38(5):488-93 - PubMed

Publication Types